ゲノム不安定性の過程における空間的および時間的な多様性は,肺がんの進化を定義する

Elza C de Bruin¹, Nicholas McGranahan², Richard Mitter³

¹Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6BT, UK.

Science (New York, N.Y.)

|October 11, 2014

まとめ

非小細胞肺癌 (NSCLC) のゲノム解析は,枝分かれした進化と重要な腫瘍内異質性を明らかにしています. ドライバー変異と不安定性を含むこれらの複雑なゲノム変化は,NSCLCの治療における課題に寄与しています.

科学分野:

腫瘍学腫瘍学
ゲノミクスゲノミクスとは
癌進化進化する

背景:

非小細胞肺がん (NSCLC) は,部分的には複雑なゲノム変異のために,予後が悪い.
NSCLCにおける空間的および時間的ゲノム変化を理解することは,治療結果の改善に不可欠です.

研究の目的:

人間のNSCLCの空間的および時間的なゲノム進化を解剖する.
NSCLCの異質性のゲノム基盤とその予後への影響を特定する.

主な方法:

7つの手術可能なNSCLC腫瘍から25の空間的に異なる領域のシーケンシング.
APOBECに関連した活動を含むコピー番号の変更,転位,変異の分析.
現在および元喫煙者の腫瘍における変異パターンの比較分析.

主要な成果:

枝分かれした進化パターンの証拠 NSCLCでは,ドライバー変異が異なる段階で現れる.
複製番号の変更や転位を含むゲノム変異における突発的な腫瘍内異質性.
喫煙者における突然変異シグネチャーの変化,喫煙関連突然変異の減少とAPOBEC関連突然変異の増加.
サブクローン多様化に先立つ元喫煙者におけるゲノム複製イベントの特定,長期の潜伏期間を示唆する.

結論:

地域的に異なるドライバー変異とNSCLCにおける広範囲にわたるゲノム不安定は,治療戦略を複雑にします.
NSCLCの進化の異質でダイナミックな性質は,治療の成功に重大な課題をもたらす.
これらの進化的動態を理解することは,NSCLCに対するより効果的な治療法の開発の鍵です.

さらに関連する動画

11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.0K

05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

550

関連する概念動画

02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.2K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

12.2K

02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.0K

02:53

Adaptive Mechanisms in Cancer Cells

5.6K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

5.6K

02:07

Tumor Progression

6.1K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

6.1K

02:59

Cancer Prevention

6.5K

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

6.5K

01:30

Spontaneous and Induced Mutations

2.8K

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).